ClinicalTrialsFinder
RecruitingNCT05665244

Laryngeal Cryotherapy for Refractory Neurogenic Cough

To Determine the Efficacy of Topical Cryotherapy on Supraglottic Laryngeal Mucosa in the Treatment of Chronic Neurogenic Cough in Adult Patients

Sponsor

University of Texas Southwestern Medical Center

Enrollment

28 participants

Start Date

Dec 26, 2022

Study Type

OBSERVATIONAL

Conditions

Upper-Airway Cough Syndrome

Summary

This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Adult patients 18 years or older with diagnosis of neurogenic cough
  • Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer)
  • Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD
  • Patient willing to participate in a clinical trial

Exclusion Criteria13

  • Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher)
  • Vocal fold abnormalities or impairment
  • History of asthma or other underlying lung condition not adequately treated or controlled
  • Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score >6, which would indicate moderate disease32)
  • Reported symptom of postnasal drip
  • Current smoker
  • Current neuromodulator medication use
  • Patient unwilling to participate in clinical trial or sign an informed consent
  • End stage medical disease with poor life expectancy
  • Medical instability deemed by the investigators as a contraindication for enrollment
  • Abnormal Chest X-ray
  • Abnormal pulmonary function testing (PFTs)
  • Positive local allergy panel (combined RAST testing)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELaryngeal cryotherapy

Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.

DEVICECryoprobe

Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract

Locations(1)

UT Southwestern Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05665244